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ABS TRACT
Cancer cells have a parasitic propensity in the primary host but their capacity to transit between indi-
viduals is severely restrained by two factors: a lack of a route for viable cell transfer and immune
recognition in allogeneic, secondary recipients. Several examples of transmissible animal cancers are
now recognised. In humans, the only natural route for transmission is via the haemochorial placenta
which is permissive for cell traffic. There are three special examples of this occurring in utero: maternal
to foetus, intraplacental twin to twin leukaemias and choriocarcinoma-extra-embryonic cells to mother.
We discuss the rare circumstances under which such transmission occurs.
KEYWORDS : haemochorial placenta; placental anastomoses; immune evasion; cancer clonal
markers; choriocarcinoma
INTRODUCTION
Parasite: ‘An organism that lives in or on another and
benefiting at the expense of its host’ (Oxford Modern
English Dictionary).
Cancer cells, we suggest, can be considered a uni-
cellular, parasitic entity. They are not generally
recognized as such but, by the above definition, it
can be argued that they qualify. Cancer has a clonal
origin and evolves via selection of cells with adaptive
phenotypes within tissue ecosystems [1, 2]. Sequential
acquisition of mutations equips cancer cells to become
robust [3] and emancipated from constraints on prolif-
erative expansion. They disseminate in the host via a
territorial hijack that compromises normal tissue func-
tions, imparting morbidity. This parasitic propensity
can be seen as an evolutionary legacy [4].
But there is more to being a successful parasitic
entity than simply exploiting a host. Survival or lon-
gevity as a parasitic lineage requires a suite of attri-
butes: immune evasion [5] and exploiting a viable
route for transmission between individual hosts—
coupled with proliferative immortality and mainten-
ance of genome integrity.
For a cancer clone, the most stringent bottleneck is
transmission. The other traits are frequently selected
during cancer progression in the primary host or pa-
tient. For example, genetically unstable cancers
can evade immune attack via immuno-editing or
loss of histocompatibility locus antigens (HLA) or
neoantigens [6]. The capacity of cancer cells to remove
their identity tags is even more evident under the strong
selective pressure of targeted immunotherapy [7, 8].
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Given appropriate selective pressures, enough cells and a high
mutation rate, it is perhaps to be expected that cancer clone evo-
lution should, at least very occasionally, enable between-host
transmission? The answer to this question is yes, as it has hap-
pened in several animal species. We now have several unambigu-
ous examples of transmissible cancers in animal species (Table 1)
(reviewed in [9, 10]). In these examples, cancer cells are
transferred between hosts by biting, sex or, possibly (for bivalve
molluscs), filter-feeding. These well-researched examples of con-
tagious animal cancers are very instructive in terms of immune
escape mechanisms and we may be under-estimating the number
of examples that exist. Nevertheless, the eight clear examples we
have are clonal and it seems reasonable to conclude that the
emergence of an immortal lineage of transmissible cancer cells
is an extremely rare event.
TRANSMISSIBLE CANCER IN HUMANS
Is there evidence that human cancer cells evolve a transmissible,
parasitic status? We know human cancers can avoid proliferative
senescence and impede or repair telomere attrition [11].
Proliferative immortality is signalled by the cell line HeLa (and
murine leukaemia equivalents) that still thrives many decades
after the demise of its donor [12] and appears, like canine trans-
missible venereal tumour (CTVT) and Tasmanian devil facial tu-
mour disease (DFTD), to be genomically or mutationally, complex
but stable [13].
But surely, the absence of an accessible route of viable cell
transmission and, in particular, the barrier of immune recognition
in an outbred species like contemporary Homo sapiens renders
transmission of cancer between humans, unlike in CTVT and
DFTD, highly unlikely? Two unbreachable barriers?
Several decades ago, cancer cells were deliberately trans-
planted between human individuals in experiments conducted
in the 1950s and 1960s that would now be considered unethical.
Chester Southam and colleagues at Memorial Sloan Kettering
Cancer Center inoculated cancer cells between cancer patients
and from cancer patients into ‘volunteers’ from a State
Penitentiary [14]. With one exception [15], no injected tumours
grew beyond a nodule stage, presumably because of immune
rejection.
In a less fortunate case, melanoma cells from a patient were
injected into her 80-year-old mother, in an attempt to elicit anti-
tumour immunity. The recipient died with disseminated melan-
oma some 15 months later, presumed to be originating from the
injected cells [16]. Allogenic organ or blood transplantation into
immuno-suppressed individuals has inadvertently provided an
iatrogenic route for cancer cell transfer between individuals
(Table 2).
Cancer has therefore been transmitted between individuals,
albeit, and fortunately, very rarely. And this is under highly
contrived circumstances where the two major restraints are
breached: a blood route for transmission provided or is naturally
available and immune recognition is evaded (Table 2). The only
natural route available for transfer of cancer cells between individ-
uals is via the placenta.
Placental anatomy and cell traffic
The mammalian placenta is a unique tissue where cells of two
genetically different individuals reside in close proximity with dir-
ect blood contact [17]. In this context, the developing foetus is
effectively an allograft. Humans, in common with other simian
primates, have the ancestral type of placental architecture [18]
which is both haemochorial and with maternal–foetal villus
interdigitation (Fig. 1). This provides an optimised platform for
nutritional support in the context of single offspring and long
gestational periods [18]. But this anatomical arrangement also
Table 1. Transmissible cancers in animal species
Transmission route Immuno-avoidance References
1. CTVT (one clone) Sexuala Down-regulation of MHC [82, 83]
2. Tasmanian DFTD (two clones with sub-clonal
divergence)
Bitinga Down-regulation of MHC
+ inbred host
[84–86]
3. Leukaemia in marine bivalves:
(i) soft shell clams
(ii) mussels
(iii) cockles (two clones)
(iv) golden carpet shell clams (clone derived
from another clam species)
Unknown, but suggested
to be via filter feeding
? [87, 88]
4. Transmissible Syrian hamster reticulum cell
sarcoma (multiple clones)b
? ? [89, 90]
? Uncertain.
aUnclear if transmission of cancer cells is via direct blood contact or via transfer of other fluids (saliva, seminal fluid).
bThese early reports have not been followed up and so the status of this example remains uncertain.
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brings maternal and foetal cells into a potentially hazardous li-
aison. Embryonic villous trophoblasts invade and interdigitate
into the maternal endometrial decidua and extra-villous tropho-
blasts remodel maternal arteries, replacing endothelial cells.
Embryonic, trophoblast cells are literally bathed in maternal
blood.
Effective placental function then requires resolution of two con-
flicts—inter-genomic resource competition [19, 20] and immuno-
logical disparity [21]. Several mechanisms ensure maternal
tolerance of paternal antigens on foetal cells within the placenta
(reviewed in [22–24]). The solutions employed have clear parallels
with immune evasion tactics employed by parasitic species [5]. In
the placenta, these include immune-suppression via epigenetic
silencing of T-cell attracting cytokine genes in the maternal de-
cidua [25]. Critically also, embryonic trophoblasts at the foetal–
maternal interface do not express classical and polymorphic HLA-
A and B proteins. In their place are non-polymorphic HLA-G, C and
E molecules [26] which may block NK cell and dendritic cell re-
activity [24] and promote invasiveness [27]. Additionally, tropho-
blast cells express PDL1 (programmed death ligand 1), a key
negative regulator of immune responses [28]. The trophoblastic
interface is immunologically invisible. As it needs to be to avoid
rejection of the developing embryo and foetus.
Despite its immunological quiescence, the maternal–foetal
interface is not impermeable to cell traffic. It is well documented
that normal blood cells migrate between mother and foetus, and
Table 2. Examples of inter-person transfer of cancer
Transmission route Immuno-avoidance References
1. Iatrogenic
Incidental transfer of unsuspected cancer with trans-
planted organs.
Recipient immuno-suppressed. [91, 92]
Donor cell leukaemia in recipients of bone marrow or
blood stem cell transplants.
Recipient immuno-suppressed. [93, 94]
Deliberate, immuno-therapeutic transfer. a [14–16]
Accidental transfer (needlestick) to medical worker. b [95–97]
2. Placental transfer
Leukaemia, between monozygotic twins in utero (with
monochorionic placentas).
Genetically identical. [58]
Cross placental from mother to foetus. Deletion of disparate HLA loci. [33–35]
Choriocarcinoma: embryonic trophoblast cells to
mother.
Modified HLA expression on trophoblast cells. [70]
Immune silencing by trophoblasts. [25]
aOnly grew as nodules at site of injection, except for one case of allogeneic cancer transferred to another cancer patient that metastasized [15].
bIncludes a transfer from patient to surgeon during an operation [95], accidental inoculation in the hand during biopsy [97] and transfer to a laboratory
worker from a cell line [96]. In two of these cases, the transferred cancers grew in recipients as nodules and did not disseminate possibly reflecting
immune, HLA disparate, control. However, in one case [97], the cancer metastasized.
Figure 1. Placental cellular anatomy. Foetus and placenta at 6 weeks gestation. (A)MY, myometrium; SA, spiral arteries; DD, decidua; IVS, intervillous space; CP,
chorionic plate; UC, umbilical cord; AF, amniotic fluid; VT, villous trophoblast. (B) SYN, syncytiotrophoblast; CTB, cytotrophoblast; EVT, extravillous trophoblast;
STR, stroma; FV, floating villous; AV, anchoring villous. Taken from Robbins JR, et al; PLoS Pathog 2010; 6(1); e1000732 PubMed 20107601 https://embryology.
med.unsw.edu.au/embryology/index.php/Trophoblast
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vice versa, resulting in micro-chimaerism [29, 30]. It is perhaps then
unsurprising that cancer cells can occasionally exploit this oppor-
tunity. Transmission of cancer in dogs and Tasmanian devils may
be facilitated by wounding, involving blood contact, angiogenesis,
cell motility and invasion, features shared with the placenta.
The placenta provides the only setting, to date, for natural trans-
mission of cancer cells between humans, and there are three spe-
cific and exceptional examples of this.
Maternal–foetal transfer of cancer cells
Transplacental transmission of a maternal cancer to the foetus is
exceedingly rare. One in 1000 live births involves a mother with
cancer [31] but in only a very small number of cases is maternal-
foetal transmission recorded. The first such case was in 1866 [32].
Two reviews more than a decade ago reported 15 published cases
[33, 34]. Since then, nine more have been published [35–42] or
uncovered in historical publications [43]. Given that there are
more than 100 million births in a year, worldwide, with possibly
500 000 involving a mother with cancer, just 26 or so cases re-
corded over many decades represent an exceedingly low risk (1
in 5  105).
In all the recorded cases of maternal–foetal transmission, can-
cer in the infant was of the same type as in the mother. Most of the
recorded cases are either melanoma or leukaemia/lymphoma
(Table 3). This may reflect the inherent capacity of the cell types
involved to migrate, infiltrate and metastasize. Where these were
exclusively adult type cancers—melanoma or lung cancer [34, 44],
their diagnosis in an infant is all the more striking. Formal, genetic
evidence that cancer in the infant cases was of maternal derivation
is, in most historical cases, either lacking or based solely on sex
chromosomes, i.e. a cancer with an XX karyotype in a male infant.
In one case, maternal and infant lymphoma shared the same
chromosomal translocation t(X; 1) [45]. Unambiguous evidence
for a maternal origin comes from two leukaemia cases in which
micro-satellite markers in the infant cancer were of maternal
Table 3. Materno–foetal transmission of cancer
Cancer type Age at diagnosis in offspring Genetic markers of maternal cells Reference
Leukaemia/lymphoma:
1. Lymphosarcoma birth [98]
2. Hodgkin’s disease 3 weeks [99]
3. NK cell lymphoma 4 weeks t(X; 11), XX [45]
4. AML 20 months XX [50]
5. ALL 9 months [100]
6. ALL 5 months Karyotype [101]
7. B cell lymphoma 8 months XX [37]
8. ALL 11 months Micro-satellite markers + BCR-ABL1 sequence [35]
9. NK/T lymphoma 8 months Micro-satellite markers [36]
Melanoma:
10. 8 months [102]
11. 11 days [103]
12. 7 weeks [104]
13. 7 months [105]
14. 2 months [51]
15. birth [40]
16. birth [32]
17. 7 months XX [106]
18. 6 months [38]
19. 3 months [42]
20. Lung adenocarcinoma 2 weeks XX [44]
21. SCLC 5 months XX [107]
22. SCLC 5 months [39]
23. Lung adenocarcinoma 2 months [108]
24. Neuro-endocrine cervical ca. 8 months [41]
25. Breast ca. 14 months [43]
26. Hepatic ca. birth [32]
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origin [35, 36]. Additionally, in one of these cases, we found that
both infant and maternal cancer cells shared the identical,
clonotypic BCR-ABL1 leukaemia fusion gene sequence indicating
they were derivative of the same clone [35].
Why should a foetus tolerate a maternal cancer which is, in
effect, a foreign allograft? One possibility is that the developing
immune system is preferentially tolerized by early exposure [46].
Dizygotic twin cattle are blood cell chimaeras [47] and fail to reject
twin skin allografts, an observation that led to the discovery of
neonatal, immune tolerance [46]. There is evidence that normal
human maternal cells that cross over into the developing foetus
may induce stable unresponsiveness to maternal antigens via the
activation of tolerogenic regulatory T cells [48].
Another possibility is natural selection of antigenic variants. In
a case of maternal–foetal transmission in utero of a leukaemia,
genetic analysis revealed that the offspring’s maternally derived
leukaemic cells had deleted the HLA haplotype that was disparate
between mother and offspring [35]. Maternal cancer cells that
grew in the infant offspring were therefore likely to be immuno-
logically invisible. The same process of natural immuno-selection
or -editing is common in endogenous cancer [6, 49] and is likely to
happen when there is strong selective pressure on a genetically
unstable or variable target. In another case of transmitted leukae-
mia, the mother was homozygous at HLA loci so the maternally
derived cancer cells in the infant will have been immunologically
inert or registered as ‘self’ [50].
In two cases of maternal leukaemia transmission, the clinical
presentation in the infant was unusual and very different to that in
the mother, the leukaemic cells being confined to a jaw tumour
[35] or residing in the testis [36]. This suggests some degree of
immunological constraint [35] or, possibly, residence in a
privileged (or sanctuary) site [36]. In two cases of maternally
transmitted melanoma, the tumour, though lethal in the mother,
regressed in the infant indicative of immunological recognition
[51]. Collectively, these rare cases suggest that there can be
recognition of the maternal tumour by the infant but also that
several mechanisms of immune evasion are co-opted by these
transmitted cancers.
Since normal blood cells readily migrate transplacentally, why
should maternal–foetal transmission of cancer be so infrequent?
Leukaemia and melanoma do infiltrate the placenta at a rate that
is in considerable excess of maternal cancer arising in the off-
spring [33, 52]. The proximate explanation may, in part, be that
only modest numbers of cells readily cross into the foetal circula-
tion and the probability that this migratory population includes an
HLA deletion mutant with propagating or stem cell function may
be very low. However, given enough proliferating cancer cells and
intense immunological pressure, selection of HLA mutants is very
likely. A vivid example of this comes from relapse in acute myeloid
leukaemia (AML) in the context of an allo T-cell transplant.
Transfer of HLA-mismatched T cells from a donor into a recipient
with AML can effectively suppress the leukaemia. But relapse is
common and, instructively, these relapses usually show deletion
of the mismatched HLA loci, again indicative of selection [53, 54].
Twin to twin dissemination of leukaemia in utero
Dependent upon the timing of splitting of an early embryo, mono-
zygotic twins either share (60%) a single, monochorionic pla-
centa (Fig. 2A) or develop in two separate dichorionic placentas
[55]. In the 1880s, Schatz described vascular anastomoses in
monochorionic placentas (Fig. 2B) [56]. A consequence of this
feature is blood cell migration between developing foetuses in
utero and resultant blood cell chimaerism. Unequal sharing of
blood between twins results in the relatively common twin–twin
transfusion syndrome in which there is significant morbidity and
mortality [57].
A monozygotic pair is no more at risk of any paediatric cancer
than a singleton. But a striking feature of cancer in twins is its high
rate of concordance of leukaemia. More than 100 cases of
Figure 2. Vascular anatomy of monochorionic, twin placenta. (A) Photograph of single, monochorionic placenta with dividing amnion tissue and two umbilical
cords. (B) Diagrammatic representation of monochorionic twin placenta with vascular anastomoses (labelled 1-5). F and F1 indicate umbilical cord of two twins.
Taken from Strong and Corney [55]. Original image from Schatz [109]
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concordant acute leukaemia in monozygotic twins have been re-
ported [58], the first being in 1882. Most twin cases of leukaemia
are of the common subtype of leukaemia seen in singleton chil-
dren—B-cell precursor acute lymphoblastic leukaemia (ALL) [59].
The rates of concordance in twin pairs are high, approaching
100% for infants (<18 months) but less, at 10–15% for older
children. These two have distinctly different, age-associated sub-
types of ALL [58].
Early clinical observations on pairs of twins with leukaemia
prompted the idea that concordance might arise by leukaemia
arising in one twin in utero, which then spread to the co-twin via
intraplacental anastomoses [60, 61]. The prediction was that
paired leukaemias in twins, originating in utero, should be
monoclonal.
As similar leukaemias in unrelated individuals can harbour the
same recurrent chromosomal abnormalities, testing the above
hypothesis had to wait until we had robust markers for clonality.
This was provided by leukaemia fusion genes [62]. These genetic
recombinants are formed following double-strand breaks in the
partner genes (usually on separate chromosomes). Breaks occur
within a defined intronic breakpoint region but are essentially
random or idiosyncratic. The result is that each clone has a unique
fusion gene sequence [63]. This then provides stable, sensitive
and clone-specific markers.
A systematic genetic analysis in a series of twin pairs using
clonal markers revealed that high concordance does indeed
derive, not from co-inherited susceptibility genes, but clonally
via twin-twin cellular transfer in utero [58] (Fig. 3). The sharing
of acquired, clone-specific leukaemic mutations indicates that
the concordant pairs of leukaemias are monoclonal or arise in
one cell, in one twin. The progeny, ‘pre-leukaemic’ cells then dis-
seminate to the co-twin, within the placenta. This only occurs in
those monozygotic twins that have a single or monochorionic
placenta [58]. Further mutational changes occur after birth, inde-
pendently in twins, that convert the covert pre-leukaemic clone to
overt, clinical leukaemia [64–66]. These secondary genetic events
may or (more often) may not arise, hence the concordance for
older children is 10–15%, not 100%. In twin pairs discordant for
clinical ALL, the co-twin who remains leukaemia-free nevertheless
retains covert pre-leukaemic cells that share the same initiating
genetic lesion as in the twin with overt ALL, but are effectively
‘frozen’ in their clonal evolution [65, 67].
The exceptionally high rate of concordance in infant (<18
months) leukaemia [58] suggests the initiating genetic lesion in
utero—usually an MLL fusion gene [62], is sufficient for overt leu-
kaemogenesis and genomic sequencing supports this contention
[68, 69]. Transfer of leukaemic or pre-leukaemic cells, when arising
in utero in one twin, is probably universal when the co-twins are
both monozygotic and monochorionic.
There is no evidence that paediatric solid tumour cells, though
often of embryonic or foetal origin, spread between twins in this
fashion. This may reflect the fact that only leukaemias are blood
borne at an early stage in their clonal, pre-natal evolutionary his-
tory. Clearly in the monozygotic twin context, there is little or no
prospect of immune recognition and rejection of cells derived
from a genetically identical individual. Leukaemic cells derived
from a co-twin will be immunologically ignored as ‘self’ unless
they express leukaemia-associated neoantigens. This has not
been explored. The rarity of twins in humans, and the lack of
strong heritability of twinning, means that selection for cancers
to evolve transmissibility between twins will be weak. Selection
could be greater in other animals in which it is common for off-
spring to develop in utero as twins (or larger groups).
Choriocarcinoma
Gestational choriocarcinoma arises in the placenta very rarely
during pregnancies (1 in 50 000) that can be either normal in
outcome or aborted. Most frequently, choriocarcinoma derives
from a complete hydatidiform mole [70]. The latter are usually
androgenic—the product of an egg devoid of maternal chromo-
somes and with paternal chromosomes only [71]. Hydatidiform
moles grow, benignly but tumour-like, as disordered chorionic villi
composed of trophoblastic cells and convert to invasive chorio-
carcinoma in the mother at a low frequency (1–2%). An andro-
genic tumour, such as a choriocarcinoma derived from a
hydatidiform mole has a parallel with sexual parasitism in which
the female genome is excluded from a fertilized egg [72].
Figure 3. Representation of concordant leukaemia in identical twins. f1, 2,
foetus 1, 2; Tw1, 2, twin 1, 2; ALL, acute lymphoblastic leukaemia; SNV, single
nucleotide variants; CNA, (gene) copy number alterations; founder lesion,
acquired (non-inherited) gene fusion or hyperdiploidy. Diagram illustrates
two foetuses in single placenta which share a shared blood circulation. The
leukaemia initiating mutation arises in one cell, in one foetus. But the clonal
progeny of that cell are then shared by both foetuses and present (and detect-
able) at birth in both Twins 1 and 2. After birth, essential secondary mutations
(CNA and SNV) accumulate independently in the cells of each twin leading to a
diagnosis of ALL. If one twin (of a monozygotic, monochorionic pair) has ALL,
the probability (p) of the second twin also developing ALL is10–15%, i.e. the
secondary genetic changes do not always happen
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Although choriocarcinoma is generally identified in a patient
sometime after a pregnancy, it may occasionally be identified in
the placenta itself by ultrasound or other scans and biopsy. These
intraplacental choriocarcinoma can result in disseminated dis-
ease in the mother, infant or both. It has recently been shown that
in the latter scenario, mother and infant may share a common
choriocarcinoma clone [73].
The cancer cells in choriocarcinoma derive from villus
cytotrophoblast cells that are probably trophoblastic stem
cells [74]. Both normal cytotrophoblasts and their malignant
counterparts in choriocarcinoma express matrix
metalloproteases facilitating invasive and stem cell self-renewal
signalling molecules including Nanog, the Wnt pathway and
STAT3 [75, 76] observed in other, common cancers. This suggests
the normal placental trophoblast cells inherently express, albeit
transiently, tumour-associated properties. Choriocarcinoma
readily disseminates to the maternal lungs and other organs but
is very sensitive to methotrexate or combination chemotherapy
and cure rates are high at over 90% [70]. However, this
transmitted cancer is intrinsically malignant and lethal in the ab-
sence of effective therapy.
A marked similarity between the biology of placental tropho-
blasts and cancer cells has long been recognised (reviewed in
[77]). The normal function of embryonic trophoblastic cells requires
that they are invasive of maternal tissue and, in the human pla-
centa, they are in direct contact with maternal blood and indeed can
migrate into it and are detectable in the blood of pregnant women
[78] and as mentioned above, can escape immune attack in the
placental environment by altered HLA expression and release of
immuno-suppressive molecules [25, 26]. These same physiological
adaptations of invasiveness, immunological disguise and suppres-
sion present mutant trophoblasts—choriocarcinoma cells, with a
passport to infiltrate and survive in the maternal blood.
Choriocarcinoma provides the only single example we have to
date of serial transmission of human cancer: from extra embry-
onic tissue to mother and, subsequently, to multiple recipients of
donor organs transplanted from that mother [79].
CONCLUSIONS
Cancer cells are mutant cheaters in multicellularity and, as such,
they function as endogenous, unicellular parasites. When
provided with a route for viable cell transfer, they can relocate,
adapt to immunological challenge and disseminate in a new host
individual. Serial transmission of cancer and longevity of the para-
sitic lineage is restricted to a few animal species and is a very rare
evolutionary event, or sequence of selective events involving, to
date, the emergence of just eight clones.
The only examples we have to date of natural transmission in
humans all reflect a liability inherent in the anatomy and function
of the placenta. To date, there are no examples of human cancer
transmitted by insect bites, human bites or sex.
Transmissibility is a potentially big advantage to a cancer clone.
The surprise is not that it occurs, but that it appears to be so very
rare. Immune recognition and the paucity of routes for viable cell
trafficking are certainly major restraints [80]. But cancer cell viru-
lence may be another. In parasitic species, there is a trade-off
between virulence and transmission and, generally, virulence is
modulated so that parasites can transmit before host death
occurs [81]. When cancers are well advanced in evolutionary tra-
jectory and metastatic, they are more likely to have the robustness
and suite of phenotypes required for transmission. This would
include a sizeable stem cell fraction. Cells with self-renewal cap-
acity would be essential for transmission and recapitulation of a
cancer. On the other hand, advanced cancers are virulent and
more likely to be lethal to the patient. The primary host is therefore
likely to die before the cancer can transmit. Even if a cancer does
transmit successfully to a second host, then it is likely to be meta-
static in this host soon after infection and to kill the secondary
host before transmission to a third host can take place. It may
therefore be that the intrinsic relationship between transmission
potential on the one hand, and metastasis and virulence on the
other, in most cancers makes their persistent transmission un-
likely. The eight cancer clones that have achieved this in animal
species all likely owe their transmission success to having
weakened this link.
The rare instances of transmission in humans are nevertheless
dramatic and distressing. Although they vividly illustrate trans-
mission potential, evolutionary trajectory is abated as transmis-
sion is not serial, and aborts with the first recipient. Not a very
successful parasite then; and one that poses no public health risk.
Malignant cancer cells are perhaps best described as parasites
with incipient transmission potential. The anatomy of the human
placenta provides a rare opportunity that is, thankfully, only very
rarely exploited.
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